Cediranib is primarily used in the field of oncology as a potent inhibitor of vascular endothelial growth factor receptors (VEGFRs). It is employed to hinder the growth of new blood vessels that supply tumors, a process known as angiogenesis. By blocking VEGFRs, cediranib effectively starves tumors of the necessary nutrients and oxygen, thereby slowing their growth and spread. This makes it a valuable component in the treatment of various cancers, including ovarian cancer, colorectal cancer, and glioblastoma. In clinical settings, cediranib is often used in combination with other chemotherapeutic agents or radiation therapy to enhance its efficacy. Its ability to target multiple pathways involved in tumor angiogenesis and progression underscores its significance in modern cancer treatment strategies.